{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:08:04Z","timestamp":1770192484305,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20241128"],"award-info":[{"award-number":["BK20241128"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273152"],"award-info":[{"award-number":["82273152"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503879"],"award-info":[{"award-number":["82503879"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M761211"],"award-info":[{"award-number":["2024M761211"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euros.2025.11.004","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T21:01:47Z","timestamp":1764622907000},"page":"36-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Consolidative Radical Cystectomy Following Neoadjuvant Tislelizumab Plus Gemcitabine and Cisplatin in Clinically Lymph Node\u2013positive Bladder Cancer: A Prospective Study"],"prefix":"10.1016","volume":"83","author":[{"given":"Juntao","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongjie","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianshuo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingkai","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3589-2507","authenticated-orcid":false,"given":"Qiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2025.11.004_b0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.11.004_b0010","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.11.004_b0015","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/s43018-024-00822-0","article-title":"Neoadjuvant gemcitabine-cisplatin plus tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial","volume":"5","author":"Li","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.euros.2025.11.004_b0020","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1200\/JCO.24.00576","article-title":"First results of NURE-Combo: a phase II study of neoadjuvant nivolumab and nab-paclitaxel, followed by postsurgical adjuvant nivolumab, for muscle-invasive bladder cancer","volume":"42","author":"Mercinelli","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.11.004_b0025","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.euros.2025.11.004_b0030","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.euros.2025.11.004_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.09.015","article-title":"Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer\u2014results of a nationwide population-based study","volume":"69","author":"Hermans","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euros.2025.11.004_b0040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2025.11.004_b0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euros.2025.11.004_b0050","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41585-023-00842-y","article-title":"Management of patients with muscle-invasive bladder cancer with clinical evidence of pelvic lymph node metastases","volume":"21","author":"Grobet-Jeandin","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euros.2025.11.004_b0055","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.ccell.2025.03.023","article-title":"Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma","volume":"43","author":"An","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euros.2025.11.004_b0060","article-title":"First-line PD-1 blockade combined with chemotherapy for stage IV penile squamous cell carcinoma: a multicenter retrospective study","volume":"23","author":"Xiong","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euros.2025.11.004_b0065","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/bju.16836","article-title":"The role of primary tumour site surgery in metastatic UTUC: a systematic review and meta-analysis","volume":"136","author":"Cella","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2025.11.004_b0070","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euros.2025.11.004_b0075","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2025.04.019","article-title":"Characterization of patients with lymph node only metastatic urothelial carcinoma treated with nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone from the CheckMate 901 trial","volume":"88","author":"Galsky","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.11.004_b0080","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2025.05.015","article-title":"Consolidative surgery for advanced urothelial carcinoma following induction enfortumab vedotin and\/or immune checkpoint inhibitor therapy: a multicenter analysis","volume":"88","author":"Roberson","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.11.004_b0085","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.euo.2023.07.011","article-title":"Proposal for a novel histological scoring system as a potential grading approach for muscle-invasive urothelial bladder cancer correlating with disease aggressiveness and patient outcomes","volume":"7","author":"Eckstein","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euros.2025.11.004_b0090","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1200\/JCO.23.00363","article-title":"Perioperative chemoimmunotherapy with durvalumab for muscle-invasive urothelial carcinoma: primary analysis of the single-arm phase II trial SAKK 06\/17","volume":"41","author":"Cathomas","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.11.004_b0095","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2023.41.6_suppl.448","article-title":"HCRN GU14-188: Phase Ib\/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer","volume":"41","author":"Brown","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.11.004_b0100","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.11.004_b0105","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1200\/JCO.2024.42.16_suppl.4516","article-title":"Avelumab (A) as neoadjuvant therapy in patients (pts) with muscle-invasive urothelial carcinoma (MIUC): survival data of AURA trial, Oncodistinct 004","volume":"42","author":"Blanc","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euros.2025.11.004_b0110","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0022-5347(05)66533-0","article-title":"Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer","volume":"165","author":"Herr","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2025.11.004_b0115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ejso.2013.01.003","article-title":"Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience","volume":"39","author":"Meijer","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.euros.2025.11.004_b0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bju.16319","article-title":"The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer","volume":"134","author":"von Deimling","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2025.11.004_b0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.11.004_b0130","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1007\/s00330-020-07572-4","article-title":"Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer","volume":"31","author":"Elsholtz","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.euros.2025.11.004_b0135","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232387","article-title":"MRI versus dual-energy CT in local-regional staging of gastric cancer","volume":"312","author":"Li","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.euros.2025.11.004_b0140","first-page":"1050","article-title":"Performance of MRI-based Node-RADS scoring system for the assessment of lymph node metastasis in bladder cancer patients","volume":"39","author":"Bai","year":"2024","journal-title":"J Clin Urol"},{"key":"10.1016\/j.euros.2025.11.004_b0145","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","article-title":"The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes","volume":"185","author":"Huang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.euros.2025.11.004_b0150","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jtho.2023.02.010","article-title":"Selective mediastinal lymph node dissection strategy for clinical T1N0 invasive lung cancer: a prospective, multicenter, clinical trial","volume":"18","author":"Zhang","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.euros.2025.11.004_b0155","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","article-title":"Omitting axillary dissection in breast cancer with sentinel-node metastases","volume":"390","author":"de Boniface","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.11.004_b0160","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euros.2025.11.004_b0165","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euros.2025.11.004_b0170","article-title":"Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer","volume":"5","author":"Galsky","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.euros.2025.11.004_b0175","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","article-title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients","volume":"28","author":"Sanmamed","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2025.11.004_b0180","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.euros.2025.11.004_b0185","article-title":"CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.euros.2025.11.004_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113762","article-title":"CircFAM64A(3) promoted bladder cancer proliferation and inhibited CD8 + T cell via sponging to miR-149-5p and activated IL-6\/JAK\/STAT pathway","volume":"145","author":"Zhuang","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.euros.2025.11.004_b0195","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12943-023-01826-7","article-title":"Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies","volume":"22","author":"Muhammad","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.euros.2025.11.004_b0200","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1073\/pnas.1812266115","article-title":"Blocking IL-1\u03b2 reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation","volume":"116","author":"Kaplanov","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.euros.2025.11.004_b0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.annonc.2023.10.125","article-title":"Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review","volume":"35","author":"Prelaj","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euros.2025.11.004_b0210","article-title":"Non-invasive tumor budding evaluation and correlation with treatment response in bladder cancer: a multi-center cohort study","volume":"12","author":"Li","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.euros.2025.11.004_b0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41416-019-0479-5","article-title":"Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features","volume":"121","author":"Karamitopoulou","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euros.2025.11.004_b0220","doi-asserted-by":"crossref","first-page":"3982","DOI":"10.1158\/0008-5472.CAN-16-3292","article-title":"Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas","volume":"77","author":"Dongre","year":"2017","journal-title":"Cancer Res"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325024619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325024619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T21:08:48Z","timestamp":1770152928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168325024619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"alternative-id":["S2666168325024619"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2025.11.004","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consolidative Radical Cystectomy Following Neoadjuvant Tislelizumab Plus Gemcitabine and Cisplatin in Clinically Lymph Node\u2013positive Bladder Cancer: A Prospective Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2025.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}